Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Maximize Your Portfolio with Data Driven ...

Spire Wealth Management bought a new position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) during the 4th quarter, ...

Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.

SG Americas Securities LLC cut its position in Biohaven Ltd. (NYSE:BHVN – Free Report) by 45.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,001 shares ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...